Open an account

Geron

GERN · NASDAQ

$1.24+$0.04 (+3.33%)TodayMarket closed ·
Prev close $1.20

About GERN

Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 258 full-time employees. The firm develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. The company is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.

Employees
258
Headquarters
Foster City, California
Listed
Jul 31, 1996
Sector
Health Care
Industry
Biotechnology
Website
geron.com

GERN key statistics

Market cap
770.97M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
7.71M
Volume
3.56M
Open price
$1.20
High today
$1.24
Low today
$1.18
52 Week high
$2.01
52 Week low
$1.04

Geron (GERN) at a glance

As of Oct 20, 2026, Geron (GERN) shares are priced at $1.24, giving the company a market cap of 770.97M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.18 and $1.24. The current price is 5.1% above the day's low and 0.0% below its high.

Volume so far is 3.56M shares, below the average of 7.71M shares a day.

Over the past year Geron has ranged from $1.04 to $2.01, and now sits 21% of the way up that range.

Geron met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.02 per share against an estimate of -$0.0092.

The average analyst price target is $4.34, 249.6% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $4.34
Low
$3.03
Now
$1.24
High
$6.30

GERN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 32.3% on average.

  1. Q3 FY24: reported -$0.04 per share against an estimate of -$0.0854
  2. Q4 FY24: reported -$0.04 per share against an estimate of -$0.0462
  3. Q1 FY25: reported -$0.03 per share against an estimate of -$0.0386
  4. Q2 FY25: reported -$0.02 per share against an estimate of -$0.0311
  5. Q3 FY25: reported -$0.03 per share against an estimate of -$0.0337
  6. Q4 FY25: reported -$0.02 per share against an estimate of -$0.0323
  7. Q1 FY26: reported -$0.01 per share against an estimate of -$0.0211
  8. Q2 FY26: reported -$0.02 per share against an estimate of -$0.0092

GERN news

  • Press releasePRNewswire

    Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

  • Press releaseBusiness Wire

    Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

  • Press releasePRNewswire

    Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

  • Press releasePRNewswire

    Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

  • Press releaseBusiness Wire

    Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

  • Press releasePRNewswire

    Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm

  • Press releasePRNewswire

    Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

Similar companies

Companies in the same industry as Geron

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.